An anonymous reader shares a report: Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials, CEO Stephane Bancel said in an interview with Bloomberg TV on Thursday. "You cannot make a return on investment if you don't have access to the U.S. market," Bancel told Bloomberg TV on the sidelines of the World Economic Forum in Davos. Bancel said regulatory delays and little support from the authorities make the market size "much smaller."

Read more of this story at Slashdot.

An anonymous reader quotes a report from the New York Times: Weight-loss drugs like Ozempic have transformed millions of lives with easily administered treatments and quick results. Now it turns out the dropped pounds may have a surprising perk for airlines, too: lower fuel costs, as slimmer passengers lighten their aircraft's loads. According to a study published last week by Jefferies, a financial services firm, the four largest U.S. carriers -- American Airlines, Delta Air Lines, Southwest Airlines and United Airlines -- could together save as much as $580 million per year on fuel thanks to weight-loss drugs, known as GLP-1s. One in eight U.S. adults said they were taking a GLP-1 in a November survey published by KFF, a nonprofit health research group. Fuel is among airlines' largest expenses. The Jefferies study estimates that the four airlines will together consume 16 billion gallons of fuel in 2026 at a total cost of $38.6 billion, nearly 20 percent of their total expenses. The savings from skinnier passengers would amount to just 1.5 percent of fuel costs. But airlines and pilots must scrutinize even the smallest changes to a plane's weight and balance, and a lighter payload means each jet burns less fuel to generate the thrust necessary to fly. Investors could also stand to benefit: The researchers estimated that a 2 percent reduction in aircraft weight could boost earnings per share by about 4 percent. "Please note savings are before any lost snack sales," the Jefferies analysts added.

Read more of this story at Slashdot.

Many people who stop using weight loss drugs will return to their previous weight within two years, a new review of existing research has found. CNN adds: This rate of weight regain is significantly faster than that seen in those who have lost weight by changing other lifestyle factors, such as diet and exercise, rather than relying on GLP-1 medications, researchers from the University of Oxford report in a paper published Wednesday in The BMJ journal. GLP-1, which stands for glucagon-like peptide-1, is a hormone naturally made by the body that helps signal to the brain and the gut that it's full and doesn't need to eat any more. Weight loss drugs mimic the action of this hormone by increasing the secretion of insulin to lower blood sugar. They also slow the movement of food through the digestive tract, which helps people feel full more quickly and for longer, and they work in the brain to reduce appetite.

Read more of this story at Slashdot.

An anonymous reader quotes a report from DealBook: Fifteen years ago, Daniel Ek broke into America's digital-content wars with his streaming music start-up, Spotify, which has turned into a publicly traded company with a $110 billion market value. Now he and his business partner, the Swedish entrepreneur Hjalmar Nilsonne, aim to crack a higher-stakes consumer market: American health care. The pair plan to bring Neko Health, the health tech start-up they founded in 2018, to New York this spring, DealBook is first to report. Mr. Ek and Mr. Nilsonne hope to capitalize on the growing number of prevention-minded Americans who are hungry to track their biometric data. Whether through wearables like Oura rings or more intensive screenings, consumers are turning to technology to improve their health and help spot the early onset of some big killers, including cardiovascular and metabolic diseases. The United States will be the third market, after Sweden and Britain, for Neko Health, which offers full-body diagnostic scans and is valued at roughly $1.7 billion. [...] Mr. Nilsonne and Mr. Ek said Neko Health's big aim was to change the health care model, in which spending across much of the developed world skyrockets but longevity gains have stalled. They want to make their noninvasive scans as routine as an annual checkup. The company, which advertises its service as "a health check for your future self," did not say what the U.S. scans would cost. But in Stockholm, an hourlong visit at one of its clinics costs 2,750 Swedish krona (about $300). Prenuvo's and Ezra's most comprehensive scans can cost $3,999. [...] Neko Health's technology differs from that of many of its U.S. rivals. It does not use M.R.I. or X-rays, instead relying on scores of sensors and cameras and a mix of proprietary and off-the-shelf technologies to measure heart function and circulation, and to photograph and map every inch of a patient's body looking for cancerous lesions. At the moment, the company's biggest challenge is scaling. [...] Mr. Nilsonne said Neko Health scans have detected the early onset of diseases or serious medical conditions for thousands of its patients. But the medical community is divided on the need for proactive screening technologies. The fear is that mass adoption could spur a wave of false positives and send healthy people to seek follow-up medical advice, overwhelming an already swamped health care system. Mr. Ek and Mr. Nilsonne believe they have built a better solution. And now they're ready to test it in the U.S. market.

Read more of this story at Slashdot.

Doctors say they have achieved the previously impossible -- restoring sight and preventing blindness in people with a rare but dangerous eye conditon called hypotony. From a report: Moorfields hospital in London is the world's first dedicated clinic for the disorder and seven out of eight patients given the pioneering treatment have responded to the therapy, a pilot study shows. One of them -- the first-ever -- is Nicki Guy, 47, who is sharing her story exclusively with the BBC. She says the results are incredible: "It's life-changing. It's given me everything back. I can see my child grow up. "I've gone from counting fingers and everything being really blurry to being able to see." Currently, she can see and read most lines of letters on an eye test chart. She is one line away from what is legally required for driving - a massive change from being partially sighted, using a magnifying glass for anything close up and having to navigate around the house and outside largely using memory. "If my vision stays like this for the rest of my life it would be absolutely brilliant. I may not ever be able to drive again but I'll take that!" she says. With hypotony, pressure within the eyeball becomes dangerously low, leading it to cave in on itself.

Read more of this story at Slashdot.

Microbiology had its golden age in the late nineteenth century, when researchers identified the bacterial causes of tuberculosis, cholera, typhoid, and a dozen other diseases in rapid succession. Antibiotics had theirs in the mid-twentieth century. Both booms eventually slowed. Vaccine development, by contrast, appears to be speeding up -- and the most productive era may still lie ahead, Works in Progress writes in a story. In the first half of the 2020s alone, researchers delivered the first effective vaccines against four different diseases: Covid-19, malaria, RSV and chikungunya. No previous decade matched that output. The acceleration rests on infrastructure that took two centuries to assemble. Edward Jenner's 1796 smallpox vaccine was a lucky accident he didn't understand. Louis Pasteur needed ninety years to turn that luck into systematic methods -- attenuation and inactivation -- that could be applied to other diseases. Generations of scientists then built the supporting machinery: Petri dishes for bacterial culture, techniques to keep animal cells alive outside the body, bioreactors for industrial production, sterilization and cold-chain logistics. Those tools have now compounded. Cryo-electron microscopy reveals viral proteins atom by atom, a capability that directly enabled the RSV vaccine after earlier attempts failed. Genome sequencing costs collapsed from roughly $100 million per human genome in 2001 to under $1,000 by 2014, according to data from the National Human Genome Research Institute. The mRNA platform, refined through work by Katalin Kariko, Drew Weissman, and others, allows vaccines to be redesigned in weeks rather than years. The trajectory suggests more breakthroughs are possible. Whether they arrive depends on continued investment, however.

Read more of this story at Slashdot.

sinij shares a news release from the Utah Department of Commerce: The state of Utah, through the Utah Department of Commerce's Office of Artificial Intelligence Policy, today announced a first-of-its-kind partnership with Doctronic, the AI-native health platform, to give patients with chronic conditions a faster, automated way to renew medications. This agreement marks the first state-approved program in the country that allows an AI system to legally participate in medical decision-making for prescription renewals, an emerging model that could reshape access to care and ultimately improve care outcomes. Politico provides additional context in its reporting: In data shared with Utah regulators, Doctronic compared its AI system with human clinicians across 500 urgent care cases. The results showed the AI's treatment plan matched the physicians' 99.2 percent of the time, according to the company. "The AI is actually better than doctors at doing this," said Dr. Adam Oskowitz, Doctronic co-founder and an associate professor of surgery at the University of California San Francisco. "When you go see a doctor, it's not going to do all the checks that the AI is doing." Oskowitz said the AI is designed to err on the side of safety, automatically escalating cases to a physician if there's any uncertainty. Human doctors will also review the first 250 prescriptions issued in each medication class to validate the AI's performance. Once that threshold is met, subsequent renewals in that class will be handled autonomously. The company has also secured a one-of-a-kind malpractice insurance policy covering an AI system, which means the system is insured and held to the same level of responsibility as a doctor would be. Doctronic also runs a nationwide telehealth practice that directs patients to doctors after an AI consultation. In Utah, patients who use the system will visit a webpage that verifies they are physically in the state. Then the system will pull the patient's prescription history and offer a list of medications eligible for renewal. The AI walks the patient through the same clinical questions a physician would ask to determine whether a refill is appropriate. If the system clears the renewal, the prescription is sent directly to a pharmacy. The program is limited to 190 commonly prescribed medications. Some medications -- including pain management and ADHD drugs as well as injectables -- are excluded for safety reasons.

Read more of this story at Slashdot.

Scientists at Melbourne's Peter Doherty Institute for Infection and Immunity are working on a Crispr-based treatment -- delivered as a nasal spray or injection -- that could stop influenza infections by targeting the virus's RNA and disrupting its ability to replicate inside human cells. The approach uses the Cas13 enzyme, a lesser-known cousin of the DNA-cutting Cas9, which can be engineered to seek out conserved regions of influenza's genetic code that are found in virtually all flu strains and are crucial to the virus's survival. The delivery mechanism would use lipid nanoparticles to ferry two molecular instructions to flu-infected cells in the respiratory tract: an mRNA that tells cells to produce Cas13 and a guide RNA that directs the enzyme to specific parts of the influenza virus's code. Cas13 then cuts the viral RNA and effectively stops the infection at the genetic level, Sharon Lewin, the infectious diseases physician leading the project, told Wired. Early safety testing at Harvard's Wyss Institute used a "lung on a chip" model to examine whether human cells producing Cas13 could fight off flu strains including H1N1 and H3N2. The institute's founding director Donald Ingber says the studies showed no off-target effects.

Read more of this story at Slashdot.

An anonymous reader shared this report from the Independent: Candida auris, a type of invasive yeast that can cause deadly infections in people with weakened immune systems, has infected at least 7,000 people [in 2025] across 27 U.S. states, according to data from the Centers for Disease Control and Prevention. The fungus, which can spread easily in healthcare settings such as hospitals and nursing homes, is gaining virulence and spreading at an "alarming" rate, the CDC says. Some strains of the fungus are particularly troublesome — and even considered a superbug — because they're resistant to all types of antibiotics used to treat fungal infections, The Hill reports. While healthy people may be able to fight off the infection on their own, the fungus can be deadly, especially in healthcare settings, where it can quickly spread amongst a vulnerable population. "If you get infected with this pathogen that's resistant to any treatment, there's no treatment we can give you to help combat it. You're all on your own," Melissa Nolan, an assistant professor of epidemiology and biostatistics at the University of South Carolina, told Nexstar... A recent study found that Candida auris is gaining virulence and spreading rapidly, not just in the U.S., but also globally. Candida auris has already been found in at least 61 countries on six continents. Some context from Newsweek: There are strategies available to combat Candida auris infection. While the superbug can develop ways to evade the immune response, vaccination and treatment strategies are possible, but researchers would like them to be strengthened. Four classes of antifungal drugs are currently available, with varying degrees of efficacy, and three new drugs are currently in trials or at newly approved stages

Read more of this story at Slashdot.

The Wall Street Journal reports that a growing number of tech startups are stocking offices with free nicotine pouches as founders and employees chase sharper focus and stamina in hyper-competitive AI-era work environments. The Wall Street Journal reports: Earlier this year, two nicotine startups -- Lucy Nicotine and Sesh -- made branded vending machines filled with flavored products for analytics company Palantir Technologies. Both machines are in the company's Washington, D.C., offices. The pouches are free for employees and guests over the age of 21, a spokeswoman for Palantir said. Palantir pays to stock the nicotine products. Alex Cohen, a startup founder based in Austin, Texas, said he was first exposed to nicotine pouches in the workplace after seeing tins of Zyns on the desks of his software engineers. His company, Hello Patient, makes AI-powered healthcare-communication software. "They were very productive, so I thought maybe there's something here," he said. Those engineers soon asked him if he could buy it for the office. Cohen said he initially bought the nicotine pouches as a joke for social media. He posted a picture of a drawer in his startup's office filled with nicotine pouches made by different brands with the caption, "We're hiring." "Then, I accidentally got addicted," said Cohen. He said he uses around two to three pouches a day. His go-to flavors are mango or minty. Cohen said he has attention-deficit/hyperactivity disorder, or ADHD, and he has found that the pouches can provide a quick productivity boost. "It helps with reining in my focus because it is a stimulant," he said. Today, Hello Patient has a nicotine-pouch fridge in its office kitchen.

Read more of this story at Slashdot.

A study by a Singapore government agency has found that children exposed to high levels of screen time before age two showed brain development changes linked to slower decision-making and higher anxiety in adolescence, adding to concerns about early digital exposure. From a report: The study was conducted by a team within the country's Agency for Science, Technology and Research and the National University of Singapore, and published in The Lancet's eBioMedicine open access journal. It tracked 168 children for more than a decade, and conducted brain scans on them at three time points. Heavier screen exposure among very young children was associated with "accelerated maturation of brain networks" responsible for vision and cognitive control, the study found. The researchers suggested this may have been the result of "intense sensory stimulation that screens provide." They found that screen time measured at ages three and four, however, did not show the same effects. Those children with "altered brain networks" took longer to make decisions when they were 8.5, and also had higher anxiety symptoms at age 13, the study said.

Read more of this story at Slashdot.